Skip to main content

Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

If you participated in the College of Psychiatric and Neurologic Pharmacists (CPNP) virtual program and are looking to claim credit, click on the headline above.
Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of Clinical Psychiatry.
The availability of new drugs for tardive dyskinesia (TD) means clinicians have an increased responsibility to proactively screen for the disorder and treat it when detected, Psych Congress cochair Rakesh Jain, MD, MPH, said.
Researchers have developed a new scale to measure the impacts tardive dyskinesia has on patients and their caregivers, according to a poster abstract presented at Psych Congress 2017.
The US Food and Drug Administration has approved deutetrabenazine for the treatment of tardive dyskinesia in adults, Teva Pharmaceutical Industries announced.
Back to Top